← Back to Clinical Trials
Recruiting NCT07621068

NCT07621068 Hyperbaric Oxygen Therapy for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS)

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07621068
Status Recruiting
Phase
Sponsor Assaf-Harofeh Medical Center
Condition Chronic Fatigue Syndrome
Study Type INTERVENTIONAL
Enrollment 74 participants
Start Date 2026-07-19
Primary Completion 2027-06

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
Hyperbaric oxygen therapySHAM treatment

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 74 participants in total. It began in 2026-07-19 with a primary completion date of 2027-06.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

This study evaluates the effects of hyperbaric oxygen therapy (HBOT) in patients with mild to moderate CFS/ME. Participants will undergo 60 HBOT sessions over 3 months with a 3-month follow-up, including physical, cognitive, imaging, and laboratory assessments.

Eligibility Criteria

Inclusion Criteria: * Subject willing and able to read, understand and sign an informed consent * Diagnosis of mild to moderate severity of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome * Patients diagnosed with CFS for more than 1 years * Stable psychological and pharmacological treatment for more than three months prior to inclusion Exclusion Criteria: 1. Inability to attend scheduled clinic visits and/or comply with the study protocol 2. Severe and very severe cases of ME/CFS 3. History or diagnosis of, brain tumors, brain surgery, epilepsy, neurodegenerative diseases 4. Active malignancy 5. Substance use at baseline, except for prescribed cannabis if vaporized or taken PO as tincture 6. Active smokers 7. Chronic heart failure with ejection fraction of 30 or less 8. Chest pathology incompatible with pressure changes (including active asthma or COPD) 9. Ear or Sinus pathology incompatible with pressure changes (above 3 otolaryngologist visits a year) 10. Pregnancy 11. An inability to perform an awake brain MRI 12. An inability to perform Neurotrax 13. Participation in another medical study 14. HBOT for any reason prior to study enrolment

Contact & Investigator

Central Contact

Eli Kravchik, MD

✉ elikr@shamir.gov.il

📞 089779241

Principal Investigator

Eli Kravchik, MD

PRINCIPAL INVESTIGATOR

principle investigator

Frequently Asked Questions

Who can join the NCT07621068 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Chronic Fatigue Syndrome. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07621068 currently recruiting?

Yes, NCT07621068 is actively recruiting participants. Contact the research team at elikr@shamir.gov.il for enrollment information.

Where is the NCT07621068 trial being conducted?

This trial is being conducted at Zrifin, Israel.

Who is sponsoring the NCT07621068 clinical trial?

NCT07621068 is sponsored by Assaf-Harofeh Medical Center. The principal investigator is Eli Kravchik, MD at principle investigator. The trial plans to enroll 74 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology